115 related articles for article (PubMed ID: 3305945)
1. Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitors.
Manley PW; Allanson NM; Booth RF; Buckle PE; Kuzniar EJ; Lad N; Lai SM; Lunt DO; Tuffin DP
J Med Chem; 1987 Sep; 30(9):1588-95. PubMed ID: 3305945
[TBL] [Abstract][Full Text] [Related]
2. Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues.
Cross PE; Dickinson RP; Parry MJ; Randall MJ
J Med Chem; 1986 Mar; 29(3):342-6. PubMed ID: 3081722
[TBL] [Abstract][Full Text] [Related]
3. [(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors.
Martinez GR; Walker KA; Hirschfeld DR; Maloney PJ; Yang DS; Rosenkranz RP
J Med Chem; 1989 Apr; 32(4):890-7. PubMed ID: 2704033
[TBL] [Abstract][Full Text] [Related]
4. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (+/-)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)- methoxy]methyl]ethoxy]hexanoic acids.
Manley PW; Tuffin DP; Allanson NM; Buckle PE; Lad N; Lai SM; Lunt DO; Porter RA; Wade PJ
J Med Chem; 1987 Oct; 30(10):1812-8. PubMed ID: 3656356
[TBL] [Abstract][Full Text] [Related]
6. Selective and nonselective inhibition of thromboxane formation.
FitzGerald GA; Oates JA
Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
[TBL] [Abstract][Full Text] [Related]
7. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat.
Maguire ED; Wallis RB
Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221
[TBL] [Abstract][Full Text] [Related]
8. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
FitzGerald GA; Brash AR; Oates JA; Pedersen AK
J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
[TBL] [Abstract][Full Text] [Related]
9. [Synthesis and platelet aggregation inhibitory activity of analogues of 4-([2-(1H-imidazol-1-yl)-1-(4-substituted-phenyl)ethoxy]methyl)benzoic acids].
Wu QY; Yang JQ
Yao Xue Xue Bao; 1991; 26(10):741-6. PubMed ID: 1823715
[TBL] [Abstract][Full Text] [Related]
10. Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.
Ford NF; Browne LJ; Campbell T; Gemenden C; Goldstein R; Gude C; Wasley JW
J Med Chem; 1985 Feb; 28(2):164-70. PubMed ID: 3918169
[TBL] [Abstract][Full Text] [Related]
11. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors.
Korbut R; Dembińska-Kieć A; Swies J; Zmuda A; Gryglewski RJ
Thromb Haemost; 1987 Oct; 58(3):827-30. PubMed ID: 3324381
[TBL] [Abstract][Full Text] [Related]
12. Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles.
Cross PE; Dickinson RP; Parry MJ; Randall MJ
J Med Chem; 1985 Oct; 28(10):1427-32. PubMed ID: 3930740
[TBL] [Abstract][Full Text] [Related]
13. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thromboxane and 12-HPETE formation by dazoxiben and its two thiophenic acid-substituted derivatives.
Smith EF; Darius H; Ferber H; Schrör K
Eur J Pharmacol; 1985 Jun; 112(2):161-9. PubMed ID: 3896821
[TBL] [Abstract][Full Text] [Related]
15. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.
Reilly IA; FitzGerald GA
Blood; 1987 Jan; 69(1):180-6. PubMed ID: 3790723
[TBL] [Abstract][Full Text] [Related]
17. Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
Kanao M; Watanabe Y; Kimura Y; Saegusa J; Yamamoto K; Kanno H; Kanaya N; Kubo H; Ashida S; Ishikawa F
J Med Chem; 1989 Jun; 32(6):1326-34. PubMed ID: 2724303
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane a2: biosynthesis and effects on platelets.
Granström E; Diczfalusy U; Hamberg M; Hansson G; Malmsten C; Samuelsson B
Adv Prostaglandin Thromboxane Leukot Res; 1982; 10():15-58. PubMed ID: 6216781
[No Abstract] [Full Text] [Related]
19. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.
Patscheke H
Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of arachidonate metabolism by selected compounds in vitro with particular emphasis on the thromboxane A2 synthase pathway.
Tobias LD; Hamilton JG
Adv Prostaglandin Thromboxane Res; 1980; 6():453-6. PubMed ID: 6770605
[No Abstract] [Full Text] [Related]
[Next] [New Search]